Galectin-3 Expression in the Left Ventricular Interstitium of Dogs with Chronic Heart Failure: Association with Interstitial Fibrosis

2019 ◽  
Vol 38 (4) ◽  
pp. S247
Author(s):  
H.N. Sabbah ◽  
V. Singh-Gupta ◽  
R.C. Gupta
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Interstitial Fibrosis ◽  
Left Ventricular ◽  
Galectin 3

scholarly journals The Discriminatory Ability of Renalase and Biomarkers of Cardiac Remodeling for the Prediction of Ischemia in Chronic Heart Failure Patients With the Regard to the Ejection Fraction

2021 ◽  
Vol 8 ◽  
Author(s):  
Dijana Stojanovic ◽  
Valentina Mitic ◽  
Miodrag Stojanovic ◽  
Dejan Petrovic ◽  
Aleksandra Ignjatovic ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Ejection Fraction ◽  
Cystatin C ◽  
Left Ventricular ◽  
Exercise Stress ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction ◽  
Discriminatory Ability ◽  
Galectin 3

Background: Renalase has been implicated in chronic heart failure (CHF); however, nothing is known about renalase discriminatory ability and prognostic evaluation. The aims of the study were to assess whether plasma renalase may be validated as a predictor of ischemia in CHF patients stratified to the left ventricular ejection fraction (LVEF) and to determine its discriminatory ability coupled with biomarkers representing a range of heart failure (HF) pathophysiology: brain natriuretic peptide (BNP), soluble suppressor of tumorigenicity (sST2), galectin-3, growth differentiation factor 15 (GDF-15), syndecan-1, and cystatin C.Methods: A total of 77 CHF patients were stratified according to the LVEF and were subjected to exercise stress testing. Receiver operating characteristic curves were constructed, and the areas under curves (AUC) were determined, whereas the calibration was evaluated using the Hosmer-Lemeshow statistic. A DeLong test was performed to compare the AUCs of biomarkers.Results: Independent predictors for ischemia in the total HF cohort were increased plasma concentrations: BNP (p = 0.008), renalase (p = 0.012), sST2 (p = 0.020), galectin-3 (p = 0.018), GDF-15 (p = 0.034), and syndecan-1 (p = 0.024), whereas after adjustments, only BNP (p = 0.010) demonstrated predictive power. In patients with LVEF <45% (HFrEF), independent predictors of ischemia were BNP (p = 0.001), renalase (p < 0.001), sST2 (p = 0.004), galectin-3 (p = 0.003), GDF-15 (p = 0.001), and syndecan-1 (p < 0.001). The AUC of BNP (0.837) was statistically higher compared to those of sST2 (DeLong test: p = 0.042), syndecan-1 (DeLong: p = 0.022), and cystatin C (DeLong: p = 0.022). The AUCs of renalase (0.753), galectin-3 (0.726), and GDF-15 (0.735) were similar and were non-inferior compared to BNP, regarding ischemia prediction. In HFrEF patients, the AUC of BNP (0.980) was statistically higher compared to those of renalase (DeLong: p < 0.001), sST2 (DeLong: p < 0.004), galectin-3 (DeLong: p < 0.001), GDF-15 (DeLong: p = 0.001), syndecan-1 (DeLong: p = 0.009), and cystatin C (DeLong: p = 0.001). The AUC of renalase (0.814) was statistically higher compared to those of galectin-3 (DeLong: p = 0.014) and GDF-15 (DeLong: p = 0.046) and similar to that of sST2. No significant results were obtained in the patients with LVEF >45%.Conclusion: Plasma renalase concentration provided significant discrimination for the prediction of ischemia in patients with CHF and appeared to have similar discriminatory potential to that of BNP. Although further confirmatory studies are warranted, renalase seems to be a relevant biomarker for ischemia prediction, implying its potential contribution to ischemia-risk stratification.

scholarly journals The role of galectin-3 in the diagnosis and control of the effectiveness of pharmacotherapy of chronic heart failure

2017 ◽  
Vol 8 (4) ◽  
pp. 5-10
Author(s):  
K. A Giamdzhian ◽  
V. G Kukes
Keyword(s):  
Heart Failure ◽  
New York ◽  
Chronic Heart Failure ◽  
Initial Level ◽  
Heart Association ◽  
Left Ventricular ◽  
Functional Class ◽  
Clinical Value ◽  
Reduced Ejection Fraction ◽  
Galectin 3

Relevance. At present, it is urgent to develop new biomarkers that can serve as a tool for early diagnosis of the disease in order to select pharmacotherapy and further monitor its effectiveness. The goal is to evaluate the clinical value of the definition of galectin-3 in patients with chronic heart failure (CHF). Materials and methods. The study included 53 patients (31 women, 22 men) with CHF II-III functional class (FC) of the New York Heart Association (NYHA). The mean age of the patients was 71 years (95% confidence interval 68.99-74.37). A group of patients with NYHA FCh II CHF made up 14 people, a group of patients with NYHA-39 CHF III FC. The median of the initial level of the N-terminal brain natriuretic peptide (NT-proBNP) was 65.7 pmol/L, the median of the initial level of galectin-3 - 8.37 pmol/l. Results. The relationship of increased level of galectin-3 with reduced ejection fraction,% (r=-0.26, p=0.04), increased creatinine level (r=0.26, p=0.04) and increased level of NT-proBNP plasma (r=0.3, p=0.02). With other clinical indicators, such as systolic and diastolic blood pressure, heart rate, body mass index, 6-minute walk test, left ventricular mass index, glucose level, total cholesterol, glomerular filtration rate, no statistically significant association was found. A moderate correlation was obtained between the levels of NT-proBNP and galectin-3 plasma (r=0.3, p=0.02). Reduction in the level of galectin-3 after the treatment was detected in 84.3% of patients. The conclusion. Galectin-3 can serve as an additional diagnostic biomarker of CHF.

scholarly journals Galectin-3 as the marker of hypertrophy and myocardial dysfunction in males with essential hypertension, carriers of polymorphic genes of angiotensin ii type 1 receptor

2018 ◽  
Vol 24 (2) ◽  
pp. 14-21
Author(s):  
V.O. Ruzhanskaya ◽  
V.G Sivak ◽  
O.O. Sakovych ◽  
V.M. Zhebel
Keyword(s):  
Heart Failure ◽  
Essential Hypertension ◽  
Angiotensin Ii ◽  
Chronic Heart Failure ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Receptor Gene ◽  
Left Ventricular ◽  
Galectin 3

One of the main etiological causes of development of heart failure is essential hypertension. The diagnosis of heart failure is usually made on the basis of comprehensive analysis of medical history, sonographic and biochemical examination. Normal ejection fraction does not exclude dyspnea of cardiac origin. Objective: to determine the role of galectin-3 as a marker of structural and functional changes of the myocardium in males with essential hypertension and CHF, carriers of polymorphic AT1R genes, residents of Podillya region of Ukraine. In this contingent, the surveyed were studied сoncentrations of galectin-3 and brain natriuretic peptide (BNP), parameters of central and systemic hemodynamics in carriers of polymorphic variants of angiotensin II type 1 receptor gene (АТ1R) - individuals with no cardiovascular pathology (n=79), male patients with II-III degree essential hypertension (EH) and hypertrophy of the myocardium (n=62), and essential hypertension (n=50) complicated by chronic heart failure (CHF), residents of Podillya region of Ukraine, were studied. Genotyping of АТ1R gene was performed using polymerase chain reaction. Galectin-3 and brain natriuretic peptide levels were determined by enzyme immunoassay. Structural and functional parameters of myocardium were assessed by ultrasound using the apparatus “RADMIR ULTIMARA”. Statistical analysis of the results obtained was done on personal computer using standard statistical package Statistica 10.0. The data are represented as mean values (M) and standard deviations (±m). Carriers of C allele of angiotensin II type 1 receptor gene were found to be dominating among the males with essential hypertension and resultant myocardial hypertrophy. Concentrations of galectin-3 and brain natriuretic peptide were significantly higher in men with essential hypertension and essential hypertension associated with chronic heart failure, as compared to those with no cardiovascular diseases, as well as the carriers of C allele of angiotensin II type 1 receptor gene. It was found that concentrations of study biomarkers were higher in individuals with severe and eccentric left ventricular hypertrophy, as well as in those with decreased ejection fraction of the left ventricle. Therefore, those biomarkers can be used in complex diagnosis of left ventricular hypertrophy in essential hypertension and the development of chronic heart failure in such patients.

Theoretical and practical aspects of the use of biomarkers in chronic heart failure

2021 ◽  
Author(s):  
D. P. Babichev ◽  
Yu. S. Rudyk ◽  
O. O. Medentseva
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Left Ventricular Ejection Fraction ◽  
Ejection Fraction ◽  
Left Ventricular ◽  
Ventricular Ejection ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction ◽  
Cardiac Biomarker ◽  
Galectin 3

Heart failure (HF) remains a major problem in the modern healthcare system, which is a significant cause of hospitalizations, disability and mortality among the population. Left ventricular (LV) ejection fraction (EF) remains one of the main criteria for distribution HF patients into groups and on which the tactics of observation and treatment depend. The European Society of Cardiology distinguishes HF with preserved EF, HF with mid‑range EF, and HF with a reduced EF. Recently, to assess the risks, scientists have divided patients with HF into the following phenotypes according to the left ventricular ejection fraction: stable HF with preserved EF, stable HF with a reduced EF, HF with an increase in EF and HF with a decrease in EF. It has been proven that the lowest mortality rate in the HF group with an increase in EF is 17 %, and the highest mortality rate in the HF group with a decrease in EF is 43 %. From this point of view, special attention is drawn to the HF with mid‑range EF group, since the left ventricular ejection fraction in patients of this group changes more actively than in others (according to studies, after 1 year, the left ventricular ejection fraction increased in 44 % of patients, and decreased in 16 % of cases). To predict changes in the left ventricular ejection fraction, it is promising to determine the levels of biomarkers in the blood. It is known that NT‑proBNP is the most studied and informative cardiac biomarker. Its level in blood plasma correlates with the left ventricular ejection fraction, but focusing only on it is impossible to predict changes in the left ventricular ejection fraction. Moreover, the accuracy of NT‑proBNP determination in the diagnosis and prediction of heart failure is only 75 — 80 %. Other most researched biomarkers, such as galectin‑3, sST‑2, GDF‑15, and high‑sensitivity troponins, separately from each other, were ineffective in predicting changes in left ventricular ejection fraction. Therefore, a multi‑marker forecasting strategy is gaining popularity. The article talks about chronic heart failure (CHF), gives its definition and classification by the left ventricular ejection fraction. A review of modern studies demonstrating the relevance of predicting changes in left ventricular ejection fraction is given, data on the main promising cardiac biomarkers, such as NP, galectin‑3, sST‑2, GDF‑15 and highly sensitive troponins, their advantages and disadvantages in diagnosis and risk stratification in patients with CHF. Including the results of studies of furin, which is a pro‑BNP‑convertase and a promising cardiac biomarker as a component of a multimarker model for predicting the course of heart failure.

scholarly journals Galectin-3 - a modern biomarker for the diagnosis of left ventricular hypertrophy and chronic heart failure and control of treatment of patients with hypertension

2018 ◽  
pp. 30-35
Author(s):  
V. O. Ruzhanska ◽  
V. G. Sivak ◽  
T. V. Polishchuk ◽  
V. M. Zhebel
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Treatment Effect ◽  
Therapy Monitoring ◽  
Heart Association ◽  
Left Ventricular ◽  
Functional Class ◽  
Prevention And Treatment ◽  
Galectin 3 ◽  
And Control

The development of new methods for the prevention and treatment of chronic heart failure and its control is an urgent medical and social problem. In this regard, using of new biological markers of the disease may be useful for early diagnosis of the disease, predict a clinical course, monitor the effects of pharmacotherapy (personalized medicine) and play an important role in stratifying the patient's risk. In 2013, according to the recommendation of the American Heart Association, a galectin-3 was introduced into the pool of such biomarkers for prevention and treatment of chronic heart failure. Objective: to improve prediction of the course and effectiveness of the therapy for hypertension and chronic heart failure as the hypertension complication in men 40-60 years old by applying the level of galectin-3 as a biomarker. There were observed the men 40-60 years old with hypertension and chronic heart failure for the concentration of galectin-3. Also, there were observed subjects without cardiovascular pathology (n=79), the men with hypertonic disease with myocardial hypertension (n=62) and the men with chronic heart failure II-III functional class of NYHA (n=50) for the indicators of central and systemic hemodynamics. The level of galectin-3 was determined by immunoassay analysis on the equipment "Stat Fact 300". Structural and functional parameters of myocardium were assessed by an ultrasound method using the equipment "RADMIR ULTIMARA". Data statistical analysis was performed on a personal computer using standard statistical package "Statistica 10.0". All data is presented in the form of average (M) and standard deviation (± σ). It has been established that the concentration of galectin-3 significantly decreases against the background of treatment. The level of galectin-3 in the patients with the II stage of hypertonic disease with good treatment effect was close to normal values compared to those with moderate treatment effect. In terms of patients with hypertension III stage, the level of galectin-3 also decreased, indicating the possibility of therapy monitoring using this biomarker. The mathematical model of the galectin-3 influencing factors also has been determined in patients with hypertension. The boundary level of the galectin-3 has been calculated, it is counted 46.51 pg/ml. It might be assumed a moderate effect of the treatment of hypertensive patients and chronic heart failure in males.

Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure

2009 ◽  
Vol 296 (2) ◽  
pp. H435-H441 ◽  
Author(s):  
Paul Milliez ◽  
Smail Messaoudi ◽  
Johnny Nehme ◽  
Camille Rodriguez ◽  
Jane-Lise Samuel ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Ejection Fraction ◽  
Diastolic Pressure ◽  
Interstitial Fibrosis ◽  
Left Ventricular ◽  
Lv Function ◽  
Electrical Remodeling ◽  
Beneficial Effects ◽  
Protein Expressions

We tested the hypothesis that heart rate (HR) reduction, induced by the selective hyperpolarization-activated current inhibitor ivabradine (Iva), might improve left ventricular (LV) function, structure, and electrical remodeling in severe post-myocardial infarction (MI) chronic heart failure (HF). MI was produced in adult male Wistar rats. After 2 mo, echocardiography was performed before the randomization into MI and MI + Iva (10 mg·kg−1·day−1) groups. After 3 mo of treatment, echocardiography and 24-h telemetry were recorded. Cardiac collagen, mRNA, and protein expressions of angiotensin-converting enzyme (ACE) and ANG II type 1 (AT1) receptor were quantified. As a result, at 2 mo post-MI, all rats displayed severe congestive HF signs (ejection fraction < 30%). At 5 mo post-MI, body and heart weights were similar in the MI and MI + Iva groups. LV ejection fraction and LV end-diastolic pressure were worsened in the MI group, whereas both were improved with Iva. Iva reduced HR by 10.4% ( P < 0.03 vs. MI) and ventricular premature complexes by 89% ( P < 0.03) and improved HR variability (standard deviation of the RR interval) by 22% ( P < 0.05). There were no effects of Iva on PR, QRS, and QT durations. Interstitial fibrosis in the MI-remote LV was markedly reduced by Iva (4.0 ± 0.1 vs. 1.8 ± 0.1%, P < 0.005). Increases in ventricular gene and protein expressions of ACE and AT1 receptor in MI were completely blunted by Iva. In conclusion, these data indicated that HR reduction by Iva prevents the worsening of LV dysfunction and remodeling that may be related to a downregulation of cardiac renin-angiotensin-aldosterone system transcripts. Such beneficial effects of Iva on cardiac remodeling open new clinical perspectives for the treatment of severe HF.

Sign in / Sign up

Export Citation Format

Share Document